Deep brain stimulation, personal identity and policy

Research output: Contribution to journalArticle

Abstract

A range of implantable brain-interfacing devices (IBIDs) is currently in use and development for the treatment of movement disorders and disorders of mood, behaviour and thought. These include cochlear implants, deep brain stimulation (DBS), prosthetic limbs, and optogenetic interventions (the combined use of genetics and optics to control individual cells). While implantable non-brain devices, such as implantable cardioverter defibrillators, began receiving US Food and Drug Administration approval in 1980, the development of IBIDs is recent, with the approval of DBS for Parkinson's disease in 1997. The expansion in use of IBIDs from neurological to psychiatric conditions is even more recent, with current trials underway for a range of disorders including depression, OCD, addiction, Alzheimer's disease and Tourette's syndrome. Emerging applications of existing IBIDs and new devices in development differ from currently approved devices and applications in two potentially crucial ways: 1) They target conditions traditionally seen as psychiatric; and/or 2) They target and modify functions or traits tied closely to agency, personal identity and personhood. As such, understanding patients' and caregivers' conceptions of personal identity in the context of disease and treatment is important not only for the informed consent process, but also for questions of public policy.

Original languageEnglish (US)
Pages (from-to)486-492
Number of pages7
JournalInternational Review of Psychiatry
Volume23
Issue number5
DOIs
StatePublished - Oct 2011

Fingerprint

Deep Brain Stimulation
Equipment and Supplies
Brain
Psychiatry
Alzheimer Disease
Optogenetics
Personhood
Drug Approval
Tourette Syndrome
Cochlear Implants
Implantable Defibrillators
Movement Disorders
Public Policy
Informed Consent
Mood Disorders
Caregivers
Parkinson Disease
Extremities
Depression
Food

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Deep brain stimulation, personal identity and policy. / Mathews, Debra J.

In: International Review of Psychiatry, Vol. 23, No. 5, 10.2011, p. 486-492.

Research output: Contribution to journalArticle

@article{c83cddfa8c97482fbc017ed1a11c7887,
title = "Deep brain stimulation, personal identity and policy",
abstract = "A range of implantable brain-interfacing devices (IBIDs) is currently in use and development for the treatment of movement disorders and disorders of mood, behaviour and thought. These include cochlear implants, deep brain stimulation (DBS), prosthetic limbs, and optogenetic interventions (the combined use of genetics and optics to control individual cells). While implantable non-brain devices, such as implantable cardioverter defibrillators, began receiving US Food and Drug Administration approval in 1980, the development of IBIDs is recent, with the approval of DBS for Parkinson's disease in 1997. The expansion in use of IBIDs from neurological to psychiatric conditions is even more recent, with current trials underway for a range of disorders including depression, OCD, addiction, Alzheimer's disease and Tourette's syndrome. Emerging applications of existing IBIDs and new devices in development differ from currently approved devices and applications in two potentially crucial ways: 1) They target conditions traditionally seen as psychiatric; and/or 2) They target and modify functions or traits tied closely to agency, personal identity and personhood. As such, understanding patients' and caregivers' conceptions of personal identity in the context of disease and treatment is important not only for the informed consent process, but also for questions of public policy.",
author = "Mathews, {Debra J}",
year = "2011",
month = "10",
doi = "10.3109/09540261.2011.632624",
language = "English (US)",
volume = "23",
pages = "486--492",
journal = "International Review of Psychiatry",
issn = "0954-0261",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Deep brain stimulation, personal identity and policy

AU - Mathews, Debra J

PY - 2011/10

Y1 - 2011/10

N2 - A range of implantable brain-interfacing devices (IBIDs) is currently in use and development for the treatment of movement disorders and disorders of mood, behaviour and thought. These include cochlear implants, deep brain stimulation (DBS), prosthetic limbs, and optogenetic interventions (the combined use of genetics and optics to control individual cells). While implantable non-brain devices, such as implantable cardioverter defibrillators, began receiving US Food and Drug Administration approval in 1980, the development of IBIDs is recent, with the approval of DBS for Parkinson's disease in 1997. The expansion in use of IBIDs from neurological to psychiatric conditions is even more recent, with current trials underway for a range of disorders including depression, OCD, addiction, Alzheimer's disease and Tourette's syndrome. Emerging applications of existing IBIDs and new devices in development differ from currently approved devices and applications in two potentially crucial ways: 1) They target conditions traditionally seen as psychiatric; and/or 2) They target and modify functions or traits tied closely to agency, personal identity and personhood. As such, understanding patients' and caregivers' conceptions of personal identity in the context of disease and treatment is important not only for the informed consent process, but also for questions of public policy.

AB - A range of implantable brain-interfacing devices (IBIDs) is currently in use and development for the treatment of movement disorders and disorders of mood, behaviour and thought. These include cochlear implants, deep brain stimulation (DBS), prosthetic limbs, and optogenetic interventions (the combined use of genetics and optics to control individual cells). While implantable non-brain devices, such as implantable cardioverter defibrillators, began receiving US Food and Drug Administration approval in 1980, the development of IBIDs is recent, with the approval of DBS for Parkinson's disease in 1997. The expansion in use of IBIDs from neurological to psychiatric conditions is even more recent, with current trials underway for a range of disorders including depression, OCD, addiction, Alzheimer's disease and Tourette's syndrome. Emerging applications of existing IBIDs and new devices in development differ from currently approved devices and applications in two potentially crucial ways: 1) They target conditions traditionally seen as psychiatric; and/or 2) They target and modify functions or traits tied closely to agency, personal identity and personhood. As such, understanding patients' and caregivers' conceptions of personal identity in the context of disease and treatment is important not only for the informed consent process, but also for questions of public policy.

UR - http://www.scopus.com/inward/record.url?scp=84855208478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855208478&partnerID=8YFLogxK

U2 - 10.3109/09540261.2011.632624

DO - 10.3109/09540261.2011.632624

M3 - Article

C2 - 22200138

AN - SCOPUS:84855208478

VL - 23

SP - 486

EP - 492

JO - International Review of Psychiatry

JF - International Review of Psychiatry

SN - 0954-0261

IS - 5

ER -